INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA

12th International Conference on Malignant Lymphoma

 

19-22 June 2013 Lugano
Close
N. Poster
Poster title
Applicant name
Status
  161-P BURKITTS LYMPHOMAS THAT ARISE SPONTANEOUSLY IN VKMYC MICE SHARE SIMILAR MUTATIONS WITH THE HUMAN DISEASE AND ARE ACCELERATED BY DIVERSE SURVIVAL SIGNALS. marta chesi Received Received
  162-P PRO-ONCOGENIC FUNCTIONS OF HSP105 IN HUMAN B-CELL NON-HODGKIN LYMPHOMAS Massimo Di Nicola Received Received
  163-P DIMERIZATION AND MONOUBIQUITINATION OF THE PARACASPASE MALT1 ARE REQUIRED FOR THE SURVIVAL OF CELLS DERIVED FROM ABC DLBCL Margot Thome-Miazza Received Received
  166-P EBV-SPECIFIC MICRO-RNA VIA EXOSOME: A KEY INTER-CELLULAR MACHINERY BETWEEN EBV TUMOR AND TUMOR-SURROUNDING IMMUNE CELLS? Kotani Ai Received Received
  167-P RICHTER SYNDROME (RS) PROMOTER METHYLATION DIFFERS FROM DE NOVO DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) Afua Adjeiwaa Mensah Received Received
  168-P THE GENOMIC LANDSCAPE OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) Esteban Braggio Received Received
  169-P QUANTITATIVE ULTRA DEEP SEQUENCING TO CHARACTERIZE CLONAL EVOLUTION OF FOLLICULAR LYMPHOMA Richard Burack Received Received
  172-P SELECTIVE QUANTIFICATION OF BMI-1 LEVELS IN THE NUCLEI OF FOLLICULAR LYMPHOMA CELLS SHOWS ITS ASSOCIATIONS WITH EZH2 GENE MUTATION AND REDUCED OVERALL SURVIVAL, INDEPENDENT OF FLIPI Naif AlJohani Received Received
  173-P MUM-1 IS A STRONG PROGNOSTIC IMMUNOHISTOCHEMICAL MARKER IN FOLLICULAR LYMPHOMA: COMPUTERIZED IMAGE ANALYSIS OF THE FL-2000 AND PRIMA RANDOMIZED GELA TRIALS. Luc Xerri Received Received
  174-P STRONG CD180 EXPRESSION : A NEW MARKER OF MARGINAL B-CELL LYMPHOMAS Lucile BASEGGIO Received Received
  175-P Multidimensional flow cytometry for sensitive evaluation of patients with IgM MGUS or Waldenstrms Macroglobulinemia and differential diagnosis with other lymphomas Bruno Paiva Received Received
  176-P CD70 T CELLS ARE INDICATIVE OF TGF--MEDIATED IMMUNE SUPPRESSION AND PREDICT A POOR OUTCOME IN FOLLICULAR LYMPHOMA PATIENTS Zhizhang Yang Received Received
  178-P OVEREXPRESSION OF MYC, BCL2, MYC/BCL2, IGM, AS WELL AS NON-GERMINAL CENTRE B-CELL LIKE IMMUNOPHENOTYPE PREDICT A WORSE PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL IN A SERIES OF 670 DE NOVO DIFFUSE LARGE B-CELL LYMPHOMAS: A LYSA STUDY. Molina Thierry Received Received
  180-P PROGNOSTIC SIGNIFICANCE AND PHENOTYPIC MANIFESTATIONS OF MYC/BCL2 PROTEIN CO-EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) WITH EXTRANODAL ORGAN INVOLVEMENT: A REPORT OF THE INTERNATIONAL DLBCL RITUXIMAB-CHOP CONSORTIUM PROGRAM STUDY Anusha Madadi Received Received
  181-P MICRORNAS OF THE MIR-17-92 CLUSTER PREDICT FOR OUTCOME IN R-CHOP-TREATED DIFFUSE LARGE B-CELL LYMPHOMA AND ARE SIGNIFICANTLY ASSOCIATED WITH EXPRESSION OF MYC PROTEIN Rachel Culpin Received Received
  182-P GENETIC ABNORMALITIES IN B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DIFFUSE LARGE B-CELL LYMPHOMA AND BURKITT LYMPHOMA (B-UCL): THE NEBRASKA EXPERIENCE ANAMARIJA PERRY Received Received
  186-P PROGNOSTIC ROLE OF HISTOLOGICAL GRADE 3A IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA. RESULTS OF AN F2-STUDY DATABASE Monica Bellei Received Received
  188-P VIROLOGIC RESPONSE IMPROVES PROGNOSIS IN PATIENTS WITH HEPATITIS C ASSOCIATED B-CELL NON-HODGKIN LYMPHOMAS, NATIONAL ANRS HC-13 LYMPHO-C STUDY RESULTS. Jean Marie Michot Received Received
  189-P INFLUENCE OF LIFESTYLE FACTORS ON THE EXPRESSION OF TUMOR-RELATED MICROENVIRONMENT T-CELLS AND THE IMPACT ON SURVIVAL IN FOLLICULAR LYMPHOMA (FL) Andrew Evens Received Received
  190-P Comparison of CHOP v. CVP treatment in 837 United States Veterans with untreated follicular lymphoma Kenneth R. Carson Received Received
  191-P A MULTICENTER PHASE II TRIAL OF BORTEZOMIB (B) COMBINED WITH RITUXIMAB (R) THERAPY FOR UNTREATED HIGH TUMOR BURDEN (HTB) INDOLENT NON-HODGKIN LYMPHOMA (NHL) Andrew Evens Received Received
  192-P FLUDARABINE-MITOXANTRONE-RITUXIMAB REGIMEN IN UNTREATED INTERMEDIATE/HIGH-RISK FOLLICULAR NON-HODGKIN Pier Luigi Zinzani Received Received
  194-P PHARMACOKINETICS (PK), SAFETY, AND OVERALL RESPONSE RATE (ORR) ACHIEVED WITH SUBCUTANEOUS (SC) RITUXIMAB (R) PLUS CHEMOTHERAPY (CT) WERE COMPARABLE TO THOSE WITH INTRAVENOUS (IV) ADMINISTRATION IN THE 1LTREATMENT OF PATIENTS (PTS) WITH FL Chelsy Viereck Received Received
  196-P FCGR3A AND FCGR2A POLYMORPHISMS DO NOT PREDICT RESPONSE RATE OR DURATION IN FOLLICULAR LYMPHOMA PATIENTS TREATED WITH SINGLE-AGENT RITUXIMAB: A PROSPECTIVE CORRELATIVE ANALYSIS FROM THE RESORT STUDY (ECOG E4402). Brad Kahl Received Received
  199-P THE USE OF RITUXIMAB AT FIRST-LINE DOES NOT IMPAIR THE EFFICACY OF SECOND-LINE THERAPY IN PATIENTS WITH FOLLICULAR LYMPHOMA. RESULTS OF THE REFOLL STUDY BY THE FONDAZIONE ITALIANA LINFOMI (FIL). Giuseppe Rossi Received Received
  201-P TREATMENT OF FOLLICULAR LYMPHOMA WITH RADIOIMMUNOTHERAPY DATA FROM THE RADIOIMMUNOTHERAPY NETWORK, AN INTERNATIONAL DATA BASE ON DAILY CLINICAL PRACTICE Christian Scholz Received Received
  203-P A POINT SCORE SIMPLIFICATION FOR PRACTICAL USE OF THE RISK STRATIFICATION FOR SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) BASED ON HEMOGLOBIN, PLATELET COUNT, HIGH LDH LEVEL AND EXTRAHILAR LYMPHADENOPATHY. Carlos Montalban Received Received
  204-P PERFORMANCE OF THE MONOCLONAL ASSAY FOR CIRCULATING FREE LIGHT CHAINS (FLC) IN AL AMYLOIDOSIS Giovanni Palladini Received Received
  205-P B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AMONG ISRAELIS AND PALESTINIANS: DIVERSE DISEASE PATTERNS AND RISK FACTORS IN POPULATIONS IN GEOGRAPHIC PROXIMITY Ora Paltiel Received Received
  206-P EFFECT OF PLACE OF RESIDENCE AND CARE ON SURVIVAL OUTCOMES IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA Diego Villa Received Received
  207-P AN ENHANCED INTERNATIONAL PROGNOSTIC INDEX (NCCN-IPI) FOR RISK STRATIFICATION OF DLBCL PATIENTS IN THE RITUXIMAB ERA: VALIDATION USING THE BRITISH COLUMBIA CANCER AGENCY (BCCA) DATABASE Zheng Zhou Received Received
  208-P IMPACT OF GENDER, BODY MASS INDEX (BMI) AND BODY SURFACE AREA (BSA) ON OUTCOMES OF DLBCL PATIENTS TREATED WITH RITUXIMAB (R): ANALYSIS OF THE U.S. NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) DATABASE Zheng Zhou Received Received
  212-P R-CHOEP-14 IMPROVES OVERALL SURVIVAL IN YOUNG HIGH-RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA COMPARED WITH R-CHOP-14. AN UPDATED ANALYSIS WITH 5 YEARS MEDIAN FOLLOW UP OF THE POPULATION-BASED INVESTIGATION FROM THE DANISH LYMPHOMA GROUP. Anne Ortved Gang Received Received
  214-P PHASE 2 STUDY OF RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE WITH BORTEZOMIB (VCR-CAP) OR VINCRISTINE (R-CHOP) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED NON-GERMINAL CENTER B-CELL-LIKE (GCB) DLBCL Fritz Offner Received Received
  215-P RESULTS OF A PHASE 2 MULTICENTER STUDY OF THE ADDITION OF RITUXIMAB (R) TO CODOX-M/IVAC FOR UNTREATED BURKITTS LYMPHOMA (BL): IMPACT OF PLASMA AND CEREBROSPINAL FLUID (CSF) R LEVELS Andrew Evens Received Received
  216-P TUMOR EPSTEIN-BARR VIRUS (EBV) REPLICATION IS ASSOCIATED WITH EARLY-ONSET AND AGGRESSIVE BEHAVIOR OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) Jordina Rovira Solé Received Received
  217-P EPSTEIN BARR VIRUS (EBV) PRIMO-INFECTIONS (PI) AND REACTIVATION (REA) TREATMENT AFTER HEART TRANSPLANTATION, IN PREVENTION OF POST-TRANSPLANTATION LYMPHOPROLIFERATION DISEASE (PTLD). Sylvain Choquet Received Received
  218-P RISK-TAILORED CNS PROPHYLAXIS IN A MONOINSTITUTIONAL SERIES OF 194 PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED IN THE RITUXIMAB ERA Andrés Ferreri Received Received
  220-P INFLUENCE OF PRIOR RITUXIMAB ON THE RESULTS OF AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA: A GELTAMO STUDY. ALBA MARÍA REDONDO Received Received
  221-P COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) IS AN ESSENTIAL TOOL TO SUPPORT TREATMENT DECISIONS IN ELDERLY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). RESULTS OF A MULTICENTER STUDY BY THE FONDAZIONE ITALIANA LINFOMI (FIL) Alessandra Tucci Received Received
  222-P ELDERLY IPI (EIPI) IN DLBCL PTS AGE 60 Y TREATED WITH RCHOP: INTERNATIONAL VALIDATION STUDY USING DATA FROM RICOVER-60 (GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP) AND LNH 98-5 (GROUPE DETUDE DE LYMPHOME DADULTES) Ranjana Advani Received Received
  224-P TREATMENT APPROACH AND CAUSE SPECIFIC SURVIVAL IN ELDERLY PATIENTS DIAGNOSED WITH DIFFUSE LARGE B-CELL LYMPHOMA. Anna Dyszkiewicz-Korpanty Received Received
  225-P PATIENT-REPORTED SYMPTOMS ARE STILL THE SINGLE MOST IMPORTANT FACTOR FOR DETECTING LYMPHOMA RELAPSE Tarec Christoffer El-Galaly Received Received
  227-P IMMUNOGENETIC ANALYSIS OF THE B-CELL REPERTOIRE OF INDOLENT MCL WITH A SPLENIC PRESENTATION clémentine sarkozy Received Received
  230-P PREEMPTIVE IMMUNOTHERAPY WITH RITUXIMAB SIGNIFICANTLY PROLONGS THE DISEASE-FREE SURVIVAL IN PATIENTS WITH MOLECULAR RELAPSE OF MANTLE CELL LYMPHOMA David Salek Received Received
  235-P LONG-TERM FOLLOW-UP OF THE PHASE II STUDY OF SMILE CHEMOTHERAPY FOR PATIENTS WITH NEWLY-DIAGNOSED STAGE IV, RELAPSED OR REFRACTORY EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE: THE NK-CELL TUMOR STUDY GROUP (NKTSG) STUDY Ritsuro Suzuki Received Received
  239-P MANAGEMENT AND PROGNOSIS OF PATHOLOGICAL FRACTURES (PF) IN A SERIES OF 373 PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF THE BONE (THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP IELSG 14 STUDY) Silvia Govi Received Received
  241-P HIGH DOSE THERAPY WITH AUTOLOGOUS STEM CELL SUPPORT FOR PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS FROM THE ADULT LYMPHOMA WORKING GROUP OF THE JAPAN SOCIETY FOR HEMATOPOIETIC CELL TRANSPLANTATION (JSHCT) Eisei Kondo Received Received
  242-P INTENSIVE THERAPY OF THE PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA Elena Baryakh Received Received
  243-P CLINICAL FEATURES AND TREATMENT OUTCOMES OF PATIENTS WITH EXTRANODAL NK/T-CELL LYMPHOMA IN GASTROINTESTINAL TRACT: RESULTS OF MULTICENTER RETROSPECTIVE ANALYSIS Won Seog Kim Received Received
  244-P Non-coding RNAs in cerebrospinal fluid as biomarker for primary central nervous system lymphoma Alexander Baraniskin Received Received
  246-P SIMILAR CHEMOKINE RECEPTOR PROFILES IN PCNSL AND SECONDARY CNS INVOLVEMENT OF SYSTEMIC DLBCL Anna Kaisa Pasanen Received Received
  247-P RITUXIMAB IN COMBINATION WITH METHOTREXATE-BASED CHEMOTHERAPY WITH BLOOD-BRAIN BARRIER DISRUPTION IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA Nancy Doolittle Received Received
  249-P PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL): A RETROSPECTIVE ANALYSIS OF DATA FROM THE DANISH LYMPHOMA REGISTRY LYFO Danny Stoltenberg Received Received
  250-P IELSG 34 FINAL RESULTS OF A MULTICENTER PHASE II STUDY TO EVALUATE THE CLINICAL ACTIVITY AND THE SAFETY OF EVEROLIMUS IN MARGINAL ZONE B-CELL LYMPHOMAS (MZL) Annarita Conconi Received Received
  253-P RISK FACTORS AND STAGING SYSTEMS IN EARLY STAGE HODGKIN LYMPHOMA PATIENTS HAVE SIGNIFICANT IMPACT ON TREATMENT OUTCOME AFTER MODERN COMBINED MODALITY TREATMENT. Beate Klimm Received Received
  254-P DEEP INSPIRATION BREATH HOLD RADIATION THERAPY REDUCES RADIATION DOSE TO HEART IN PATIENTS TREATED FOR MEDIASTINAL HODGKIN LYMPHOMA Peter Meidahl Petersen Received Received
  255-P TAILORING THERAPY IN HODGKIN LYMPHOMA BASED ON PREDEFINED RISK FACTORS AND EARLY INTERIM PET/CT: ISRAELI H2 STUDY -PRELIMINARY REPORT ON 306 PATIENTS Eldad J Dann Received Received
  256-P PATTERNS OF FAILURE (POF) IN A RANDOMIZED PHASE III TRIAL OF ABVD VS. STANFORD V /- RADIATION THERAPY (RT) IN LOCALLY EXTENSIVE AND ADVANCED STAGE HODGKINS LYMPHOMA (HL): AN INTERGROUP STUDY COORDINATED BY THE EASTERN COOPERATIVE ONCOLOGY GROUP (E2496) Henry Wagner Received Received
  257-P PHARMACOGENETIC ANALYSIS OF CYP2B6 IN THE LRF CLL4 TRIAL: THE 6 ALLELIC VARIANT IS ASSOCIATED WITH INFERIOR EFFICACY FOLLOWING FLUDARABINE PLUS CYCLOPHOSPHAMIDE Gillian Johnson Received Received
  258-P THE PROGNOSTIC IMPACT OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA REQUIRING FIRST-LINE THERAPY Julio Delgado Received Received
  259-P A HIGH NUMBER OF LOSSES IN 11Q CHROMOSOME IS ASSOCIATED WITH SHORT TIME TO FIRST TREATMENT AND OVERALL SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. FINAL RESULTS OF DATABASE OF CLL OF SPANISH GROUP OF CYTOGENETICS AND SPANISH GROUP OF CLL JOSE-ANGEL HERNANDEZ Received Received
  260-P FLUDARABINE, RITUXIMAB, AND LENALIDOMIDE IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) Ian Flinn Received Received
  261-P PLATINUM AND HIGH-DOSE CYTARABINE-BASED REGIMENS ARE EFFICIENT IN ULTRA HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA : RESULTS OF A RETROSPECTIVE MULTICENTER STUDY Eric DUROT Received Received
  262-P CYTOKINE QUANTIFICATION IN HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS TREATED WITH IBRUTINIB AND RITUXIMAB Iris de Weerdt Received Received
  264-P THE EFFECT OF MOLECULAR SUBCLASS ON PATIENT OUTCOMES AFTER RADIOIMMUNOTHERAPY-BASED CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA Tanya Siddiqi Received Received
  265-P TREATMENT OF PERIPHERAL T-CELL LYMPHOMA WITH AGGRESSIVE INDUCTION CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT USING DENILEUKIN DIFTITOX (DD) FOR IN VIVO PURGING AND POST-TRANSPLANT THERAPY: PRELIMINARY RESULTS OF A PHASE II CLINICAL TRIAL Lawrence Kaplan Received Received
  266-P AUTOLOGOUS AND ALLOGENEIC STEM-CELL TRANSPLANTATION FOR TRANSFORMED NON-FOLLICULAR INDOLENT LYMPHOMA: A REPORT OF THE CANADIAN BLOOD AND MARROW TRANSPLANT GROUP Diego Villa Received Received
  270-P BASELINE METABOLIC TUMOR VOLUME PREDICTS PATIENTS OUTCOME IN HODGKIN LYMPHOMA cédric rossi Received Received
  271-P FDG PET-CT AFTER FIRST-LINE TREATMENT PREDICTS PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) Eukene Gainza Received Received
  272-P PROGNOSTIC VALUE OF 18FDG BASELINE FUNCTIONAL PET PARAMETERS IN PRIMARY MEDIASTINAL DIFFUSE LARGE B-CELL LYMPHOMA (PMLBCL) Luca Ceriani Received Received
  273-P 18F-FLUORODEOXYGLUCOSE (FDG) OUTPERFORMS 18F-FLUOROTHYMIDINE (FLT) IN IDENTIFYING TRANSFORMATION OF FOLLICULAR LYMPHOMA, IN PARTICULAR THROUGH HETEROGENEITY IN UPTAKE Marielle Wondergem Received Received
  274-P INTERIM PET SUVMAX REDUCTION IS SUPERIOR TO VISUAL ANALYSIS TO PREDICT PATIENTS OUTCOME IN HODGKIN LYMPHOMA Cédric rossi Received Received
  276-P COMPARATIVE ASSESSMENT OF BONE MARROW INVOLVEMENT (BMI) BY BM BIOPSY (BMB) OR POSITRON EMISSION TOMOGRAPHY (PET) IN HODGKIN LYMPHOMA (HL) Theodoros Vassilakopoulos Received Received
  277-P A NOVEL ORAL BRUTONS TYROSINE KINASE (BTK) INHIBITOR THAT DEMONSTRATES POTENT PHARMACODYNAMIC ACTIVITY THROUGH PHOSPHORYLATED BTK (P-BTK) INHIBITION, IN ADDITION TO EFFECTIVE ANTI-TUMOUR ACTIVITY IN A DLBCL XENOGRAFT MODEL) Toshio Yoshizawa Received Received
  278-P GENOMIC INSTABILITY AND ACTIVATION OF THE DNA DAMAGE RESPONSE PATHWAY IS AN INDEPENDENT PREDICTOR OF POOR PROGNOSIS AND A PROMISING TARGET FOR THERAPY IN DIFFUSE LARGE B CELL LYMPHOMA Enrico Derenzini Received Received
  279-P TARGETING SIGNALING PATHWAYS IN MYCOSIS FUNGOIDES AND SEZARY SYNDROME Wei Ai Received Received
  281-P A NEW THERAPEUTIC APPROACH FOR THE THERAPY OF B-CELL DISORDERS: DRUG-LOADED ANTI-CD20 NANOPARTICLES) Gabriele Pozzato Received Received
  284-P DARATUMUMAB, A NOVEL HUMAN CD38 MONOCLONAL ANTIBODY FOR THE TREATMENT OF B-CELL NONHODGKIN LYMPHOMA Patricia Pérez-Galán Received Received
  285-P EFFECTS OF RITUXIMAB AND GA-101 ON IN VITRO KILLING OF CELL LINES AND PATIENT LYMPHOMA CELLS BY NORMAL DONOR OR PATIENT EFFECTOR CELLS Huei Shan Wu Received Received
  289-P BENDAMUSTINE, LENALIDOMIDE, AND RITUXIMAB IN RELAPSED AND REFRACTORY LYMPHOID MALIGNANCIES Bruce Cheson Received Received
  292-P EFFICACY AND SAFETY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB (IR) IN HIGH-RISK CLL PATIENTS Jan A. Burger Received Received
  299-P PHASE II MULTICENTER STUDY OF LENALIDOMIDE IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA POST-BORTEZOMIB: MCL-001 EMERGE STUDY marybeth McKenzie Received Received
  306-P ARE MONOCLONAL ANTIBODIES NECESSARY IN THE TREATMENT OF CHILDRENS B-NON HODGKIN LYMPHOMA? Josip Konja Received Received
  308-P OUTCOME AND TOXICITY PATTERNS IN CHILDREN WITH NON-HODGKINS LYMPHOMA Oussama Abla Received Received
  309-P MANAGEMENT OF PEDIATRIC HODGKIN LYMPHOMA IN CROATIA Josip Konja Received Received
  310-P RAPID EARLY RESPONSE TO HIGH-DOSE METHOTREXATE IN AN ADOLESCENT WITH MULTIFOCAL PRIMARY CNS LYMPHOMA Oussama Abla Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon - Fri 8:15 - 15:00
07:19
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image

INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA

12th International Conference on Malignant Lymphoma

 

19-22 June 2013 Lugano
HELP LINE
Manage Orders
FAQs

CLICK HERE TO SEE A PRESENTATION OF THE NEW-LOOK POSTERSESSIONONLINE VIEWER.


Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 19/04/2013 TO 22/06/2018
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.12icml.2013 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 25/07/2013
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster








PosterSessionOnline
Logo Draft
 
Logo Cert